The United Kingdom and the United States have concluded a major bilateral deal that will maintain zero levies on British pharmaceutical exports going into the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to raise spending on medicines through the NHS. This commitment guarantees that duties on these vital exports will be held at nothing for a timeframe of the next three years.
This development follows earlier statements to dramatically increase tariffs on branded drug imports, with increases discussed as high as double the cost.
"This deal with the United Kingdom bolsters the global environment for new treatments and establishes much-needed balance to U.S.–U.K. drug exports," an announcement noted.
Trade Importance
Medicines constitute one of the the United Kingdom's most significant goods shipped to the US, which is clearly the biggest buyer for leading companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period leading up to September, the UK shipped drugs valued at over eleven billion pounds to the US. This figure represented 17.4% of British export trade in that timeframe.
"This agreement protects employment, stimulates capital expenditure and facilitates the UK to establish itself as a international leader for medical research," a government official remarked.
Specific NHS Changes
The pact entails several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new treatments to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to raise total health service expenditure on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to control costs will be capped at fifteen percent. Previously, refunds exceeded 20%.
Industry Background
The deal follows a long-running dispute between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
These tensions were heightened by assertions that American consumers were paying a premium for the same drugs than consumers in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar expansions have been announced toward American operations.
One official publicly accepted that the NHS must spend more on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the previous ten-year period.
